|
1
|
Watts C, Price SJ and Santarius T: Current
concepts in the surgical management of glioma patients. Clin Oncol
(R Coll Radiol). 26:385–394. 2014. View Article : Google Scholar
|
|
2
|
Haapasalo J, Hyartt A, Salmi M, et al:
Diagnosis and prognosis of gliomas - current prospects of molecular
diagnostics. Duodecim. 130:893–901. 2014.(In Finnish).
|
|
3
|
Peng Y, Yu S, Li H, et al: MicroRNAs:
emerging roles in adipogenesis and obesity. Cell Signal.
26:1888–1896. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palumbo S, Miracco C, Pirtoli L and
Comincini S: Emerging roles of microRNA in modulating cell-death
processes in malignant glioma. J Cell Physiol. 229:277–286. 2014.
View Article : Google Scholar
|
|
5
|
Wang Z, Wang B, Shi Y, et al: Oncogenic
miR-20a and miR-106a enhance the invasiveness of human glioma stem
cells by directly targeting TIMP-2. Oncogene. Apr 7–2014.(Epub
ahead of print). View Article : Google Scholar
|
|
6
|
Wan X, Cheng Q, Peng R, et al: ROCK1, a
novel target of miR-145, promotes glioma cell invasion. Mol Med
Rep. 9:1877–1882. 2014.PubMed/NCBI
|
|
7
|
Kwak SY, Yang JS, Kim BY, Bae IH and Han
YH: Ionizing radiation-inducible miR-494 promotes glioma cell
invasion through EGFR stabilization by targeting p190B rhoGAP.
Biochim Biophys Acta. 1843:508–516. 2014. View Article : Google Scholar
|
|
8
|
An L, Liu Y, Wu A and Guan Y: microRNA-124
inhibits migration and invasion by down-regulating ROCK1 in glioma.
PLoS One. 8:e694782013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, Li H, Han L, et al: Expression and
function of miR-27b in human glioma. Oncol Rep. 26:1617–1621.
2011.PubMed/NCBI
|
|
10
|
Cabrita MA and Christofori G: Sprouty
proteins, masterminds of receptor tyrosine kinase signaling.
Angiogenesis. 11:53–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mei Y, Bian C, Li J, et al: miR-21
modulates the ERK-MAPK signaling pathway by regulating SPRY2
expression during human mesenchymal stem cell differentiation. J
Cell Biochem. 114:1374–1384. 2013. View Article : Google Scholar
|
|
12
|
Wang C, Delogu S, Ho C, et al:
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis
via activation of MAPK and PKM2 pathways. J Hepatol. 57:577–583.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kwak HJ, Kim YJ, Chun KR, et al:
Downregulation of Spry2 by miR-21 triggers malignancy in human
gliomas. Oncogene. 30:2433–2442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tay FC, Lim JK, Zhu H, Hin LC and Wang S:
Using artificial microRNA sponges to achieve microRNA
loss-of-function in cancer cells. Adv Drug Deliv Rev. May
22–2014.(Epub ahead of print). PubMed/NCBI
|
|
15
|
Wan L, Zhang L, Fan K and Wang J: MiR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye J, Wu X, Wu D, et al: miRNA-27b targets
vascular endothelial growth factor C to inhibit tumor progression
and angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishteiwy RA, Ward TM, Dykxhoorn DM and
Burnstein KL: The microRNA -23b/-27b cluster suppresses the
metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 7:e521062012. View Article : Google Scholar
|
|
18
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: MiR-27b targets PPARgamma to inhibit growth, tumor progression
and the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar :
|
|
19
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b
are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer
Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li P, Tao L, Yang J, et al: Sprouty2 is
associated with prognosis and suppresses cell proliferation and
invasion in renal cell carcinoma. Urology. 82:253.e1–e7. 2013.
View Article : Google Scholar
|
|
21
|
Rathmanner N, Haigl B, Vanas V, Doriguzzi
A, Gsur A and Sutterlüty-Fall H: Sprouty2 but not Sprouty4 is a
potent inhibitor of cell proliferation and migration of
osteosarcoma cells. FEBS Lett. 587:2597–2605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biyashev D, Veliceasa D, Topczewski J, et
al: miR-27b controls venous specification and tip cell fate. Blood.
119:2679–2687. 2012. View Article : Google Scholar :
|
